



1625
IMAGE

PATENT
ATTORNEY DOCKET NO. 50124/005001

Certificate of Mailing: Date of Deposit: February 19, 2004

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Alma Woodberry

Printed name of person mailing correspondence


Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jackson et al.
Serial No.: 09/582,059
Filed: November 20, 2000
Title: Therapeutic Compounds

Art Unit: 1625
Examiner: Evelyn Huang
Customer No.: 21559

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY TO OFFICE ACTION

Applicants wish to thank Examiner Huang for the helpful telephonic interview of this case on Wednesday February 18, 2004. During the interview Examiner Huang suggested several amendments to claim 1. First, the Examiner suggested replacing the term “YN-Q” with “YN-R” in order to mirror the specification. Second, the Examiner proposed replacing “comparison to any opioid of formula YN-Q comprising an organic residue YN...” with “comparison to any opioid of formula YN-R wherein YN of YN-R is identical to YN of said compound and R of YN-R is H, -CH₂CH=CMe₂, phenethyl, cyclopropyl, or an alkyl of 1 to 6 carbon atoms.” Finally, the Examiner proposed replacing the limitation that YN and the amidine or guanidine group be “separated by 1 to 6 atoms” with “separated by 1 to 6 carbon atoms.” With respect to claiming the charged heterocyclic rings, the Examiner agreed to withdraw the new matter rejection if the claims were amended to read “R¹ and R³ together complete a